De Bono JS - Search Results

1

New treatment developments applied to elderly patients with advanced prostate cancer.

Mukherji D, Pezaro CJ, Shamseddine A, De Bono JS. Mukherji D, et al. Among authors: de bono js. Cancer Treat Rev. 2013 Oct;39(6):578-83. doi: 10.1016/j.ctrv.2012.12.004. Epub 2013 Jan 3. Cancer Treat Rev. 2013. PMID: 23290885 Review.

2

New therapies for castration-resistant prostate cancer: efficacy and safety.

Beltran H, Beer TM, Carducci MA, de Bono J, Gleave M, Hussain M, Kelly WK, Saad F, Sternberg C, Tagawa ST, Tannock IF. Beltran H, et al. Eur Urol. 2011 Aug;60(2):279-90. doi: 10.1016/j.eururo.2011.04.038. Epub 2011 May 4. Eur Urol. 2011. PMID: 21592649 Review.

3

Abiraterone acetate: redefining hormone treatment for advanced prostate cancer.

Pezaro CJ, Mukherji D, De Bono JS. Pezaro CJ, et al. Among authors: de bono js. Drug Discov Today. 2012 Mar;17(5-6):221-6. doi: 10.1016/j.drudis.2011.12.012. Epub 2011 Dec 19. Drug Discov Today. 2012. PMID: 22198164 Review.

4

MDV3100 for the treatment of prostate cancer.

Mukherji D, Pezaro CJ, De-Bono JS. Mukherji D, et al. Among authors: de bono js. Expert Opin Investig Drugs. 2012 Feb;21(2):227-33. doi: 10.1517/13543784.2012.651125. Epub 2012 Jan 10. Expert Opin Investig Drugs. 2012. PMID: 22229405 Review.

5

Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100.

Richards J, Lim AC, Hay CW, Taylor AE, Wingate A, Nowakowska K, Pezaro C, Carreira S, Goodall J, Arlt W, McEwan IJ, de Bono JS, Attard G. Richards J, et al. Among authors: de bono js. Cancer Res. 2012 May 1;72(9):2176-82. doi: 10.1158/0008-5472.CAN-11-3980. Epub 2012 Mar 12. Cancer Res. 2012. PMID: 22411952 Free PMC article.

6

Management of metastatic castration-resistant prostate cancer: recent advances.

Mukherji D, Eichholz A, De Bono JS. Mukherji D, et al. Among authors: de bono js. Drugs. 2012 May 28;72(8):1011-28. doi: 10.2165/11633360-000000000-00000. Drugs. 2012. PMID: 22621691 Review.

7

Cabazitaxel in metastatic castration-resistant prostate cancer.

Yap TA, Pezaro CJ, de Bono JS. Yap TA, et al. Among authors: de bono js. Expert Rev Anticancer Ther. 2012 Sep;12(9):1129-36. doi: 10.1586/era.12.88. Expert Rev Anticancer Ther. 2012. PMID: 23098113 Review.

8

Second-line treatment options in metastatic castration-resistant prostate cancer: a comparison of key trials with recently approved agents.

Bahl A, Masson S, Birtle A, Chowdhury S, de Bono J. Bahl A, et al. Cancer Treat Rev. 2014 Feb;40(1):170-7. doi: 10.1016/j.ctrv.2013.06.008. Epub 2013 Aug 16. Cancer Treat Rev. 2014. PMID: 23958310 Free article. Review.

9

Novel drugs targeting the androgen receptor pathway in prostate cancer.

Mateo J, Smith A, Ong M, de Bono JS. Mateo J, et al. Among authors: de bono js. Cancer Metastasis Rev. 2014 Sep;33(2-3):567-79. doi: 10.1007/s10555-013-9472-2. Cancer Metastasis Rev. 2014. PMID: 24390422 Review.

10

Activity of cabazitaxel in castration-resistant prostate cancer progressing after docetaxel and next-generation endocrine agents.

Pezaro CJ, Omlin AG, Altavilla A, Lorente D, Ferraldeschi R, Bianchini D, Dearnaley D, Parker C, de Bono JS, Attard G. Pezaro CJ, et al. Among authors: de bono js. Eur Urol. 2014 Sep;66(3):459-65. doi: 10.1016/j.eururo.2013.11.044. Epub 2013 Dec 17. Eur Urol. 2014. PMID: 24411987

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

514 results

Search Page